Evolving CLL Treatment Recommendations
  • CME
  • CE

In this focused text module, multidisciplinary expert faculty discuss how treatment for CLL has evolved rapidly during the past 5 years and how this has affected clinical practice, with case studies used to illustrate current therapeutic paradigms.
Nichole Fisher Headshot
Nichole Fisher, RN, BSN
Nicole Lamanna, MD
Anthony Perissinotti, PharmD, BCOP
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Registered Nurses: 0.75 Nursing contact hours
Pharmacists: 0.75 contact hours (0.075 CEUs)
Released: October 6, 2022 Expiration: October 5, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Use tumor and patient characteristics, informed by patient preference, to select optimal treatment for treatment-naive and relapsed/refractory CLL.
  • Address gaps in HCP and patient knowledge and perceptions about therapy for treatment-naive and relapsed/refractory CLL.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
CLL Society Logo
Supported by educational grants from
AbbVie Inc.
AstraZeneca
Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc.
TG Therapeutics, Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Nicole Lamanna, MD: consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Celgene, Genentech, Janssen, Loxo/Lilly, Pharmacyclics; researcher (paid to her institution): AbbVie, AstraZeneca, BeiGene, Genentech, Loxo/Lilly, MingSight, Octapharma, Oncternal, TG Therapeutics, Verastem.
Nichole Fisher, RN, BSN

Clinical Research Coordinator
Registered Nurse, Research Supervisor

Research, Oncology/Hematology
Willamette Valley Cancer Institute
Eugene, Oregon

Nichole Fisher, RN, BSN: consultant/advisor/speaker: AbbVie, TG Therapeutics.
Anthony Perissinotti, PharmD, BCOP

Hematology Clinical Pharmacist Specialist
Clinical Team Leader
, Hematology/Oncology
Adjunct Clinical Assistant Professor
University of Michigan, Michigan Medicine
Roger Cancer Center
Ann Arbor, Michigan

Anthony Perissinotti, PharmD, BCOP: consultant/advisor/speaker: AbbVie, Janssen.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant financial relationships to disclose.
Jill Sakai, PhD

Editorial Contributor

Jill Sakai, PhD, has no relevant financial relationships to disclose.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant financial relationships to disclose.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant financial relationships to disclose.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant financial relationships to disclose.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant financial relationships to disclose.
Jacqueline L. Olin, MS, Pharm.D., BCPS, FASHP, FCC
Jacqueline L. Olin, MS, PharmD, BCPS, has no relevant financial relationships to disclose.
Kristi Kay Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Kay Orbaugh, MSN, NP, AOCNP: speaker: AstraZeneca, Bristol-Myers Squibb, DSI, Gilead Sciences, Lilly, MorphoSys, Pfizer, Regeneron, Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for physicians, nurses, pharmacists, healthcare professionals, patients, and caregivers involved in the management of CLL.

Goal

The goal of this activity is to improve the competence of learners in educating and managing patients with chronic lymphocytic leukemia.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-246-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 50% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 06, 2022, through October 05, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Comentario experto de los datos de la Junta Anual de SOHO 2022 sobre inhibidores de la TQB para LLC y LCM de Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Commenti di esperti sui dati della Conferenza annuale della SOHO 2022 sugli inibitori di BTK per il trattamento di CLL e MCL, a cura di Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Expertengespräch über die Daten der Jahresversammlung der SOHO 2022 zu BTK-Inhibitoren bei CLL und MCL, von Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Commentaires d’experts sur les données de la réunion annuelle de la SOHO 2022 au sujet des inhibiteurs BTK pour le traitement de la LLC et du LCM de Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings